Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 9/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298426 | 0.96 | CNR2 (0.40) | SMN1; SMN2GAAMAPK1HTTCNR2 | |
| SCHEMBL5794141 | 0.95 | CNR2 (0.37) | SMN1; SMN2GAAMAPK1HTTCNR2 | |
| SCHEMBL4300070 | 0.94 | CNR2 (0.37) | SMN1; SMN2GAAMAPK1HTTCNR2 | |
| SCHEMBL4291147 | 0.90 | GAA (0.39) | SMN1; SMN2GAAMAPK1HTTCNR2 | |
| SCHEMBL4286902 | 0.90 | CNR2 (0.37) | SMN1; SMN2GAAMAPK1HTTCNR2 | |
| SCHEMBL4288619 | 0.86 | CNR2 (0.36) | CNR2CNR1NAAAEPHX1 | |
| SCHEMBL5793818 | 0.83 | EPHX1 (0.48) | SMN1; SMN2GAAMAPK1HTTCNR2 | |
| SCHEMBL4300197 | 0.83 | CNR2 (0.37) | HTTCNR2CNR1EPHX1 | |
| SCHEMBL4300331 | 0.83 | CNR2 (0.37) | HTTCNR2CNR1EPHX1 | |
| SCHEMBL4291227 | 0.83 | CNR2 (0.37) | HTTCNR2CNR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | claimed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | SMN1; SMN2 3876/4885GAA 3986/4885MAPK1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.